Statin prescribing in the elderly in the Netherlands: A pharmacy database time trend study

Drugs and Aging

Volumn 27, Issue 7, 2010, Pages 589-596

  Geleedst De Vooght, Marjolein ^a   Maitland Van Der Zee, Anke Hilse ^b   Schalekamp, Tom ^b   Mantel Teeuwisse, Aukje ^b   Jansen, Paul ^c  

^a Apotheek Lusse   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Elderly; HMG CoA reductase inhibitors, therapeutic use; Hypercholesterolaemia, treatment; Simvastatin, therapeutic use

Indexed keywords

ATORVASTATIN; SIMVASTATIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

AGED; ARTICLE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; AGE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DOSE RESPONSE; FACTUAL DATABASE; MIDDLE AGED; PRACTICE GUIDELINE; TIME;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NETHERLANDS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PYRROLES; SIMVASTATIN; TIME FACTORS;

EID: 77954154128     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11537330-000000000-00000     Document Type: Article

References (27)

1. Costa J, Borges M, David C, et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006; 332 (7550): 1115-1124
2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366 (9493): 1267-1278
3. PyöräläK, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15 (10): 1300-1331
4. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19 (10): 1434-1503 (Pubitemid 28470470)
5. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24 (17): 1601-1610
6. Thomas S, Van der Weijden T, Van Drenth BB, et al. NHG standard cholesterol [in Dutch]. Huisarts Wet 1999; 42 (9): 406-417
7. CBO, Kwaliteitsinstituut voor de Gezondheidszorg. Guideline cholesterol [in Dutch]. Utrecht: CBO, 1998
8. Smulders YM, Burgers JS, Scheltens T, et al. Clinical practice guideline for cardiovascular risk management in the Netherlands. Neth J Med 2008; 66 (4): 169-174
9. Walley T, Folino-Gallo P, Stephens P, et al. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 2005; 60 (5): 543-551
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet 2002; 360 (9326): 7-22
11. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630
12. Wenger NK, Lewis SJ, Herrington DM, et al. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007; 147 (1): 1-9
13. Olsson AG, Schwartz GG, Szarek M, et al. Effects of highdose atorvastatin in patients > or = 65 years of age with acute coronary syndrome (from the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study). Am J Cardiol 2007; 99 (5): 632-635
14. Neil HA, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65-75 years at randomisation: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 2006; 29 (11): 2378-2384
15. Rinfret S, Behlouli H, Eisenberg MJ, et al. Class effects of statins in elderly patients with congestive heart failure: a population-based analysis.AmHeart J 2008; 155 (2): 316-323
16. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 2001; 134 (10): 931-940
17. Afilalo J, Dugue G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analyses. J Am Coll Cardiol 2008; 51 (1): 37-45
18. Tikkanen MJ, Holme I, Cater NB, et al. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20-40 mg) in patients aged <65 versus ‡65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study). Am J Cardiol 2009; 103: 577-582
19. Teeling M, Bennett K, Feely J. The influence of guidelines on the use of statins: analysis of prescribing trends 1998- 2002. Br J Clin Pharmacol 2005; 59 (2): 227-232
20. Williams D, Bennett K, Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol 2003; 55 (6): 604-608
21. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344 (26): 1959-1965
22. Lau HS, de Boer A, Beuning KS, et al. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997; 50 (5): 619-625
23. WHO Collaborating Centre for Drug Statistics. ATC/DDD Index 2009 [online]. Available from URL: http://www. whocc.no/atcddd [Accessed 2009 Nov 10]
24. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005; 46: 1425-1433
25. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004; 291 (15): 1864-1870
26. Centraal Bureau voor de Statistiek, The Hague/Heerlen [online]. Available from URL: http://www.cbs.nl/nl-NL/menu/ themas/bevolking/cijfers/default.htm [Accessed 2009 Nov 10]
27. Kaplan GA, Keil JE. Socioeconomic factors and cardiovascular disease: a review of the literature. Circulation 1993; 88: 1973-1998